New drug trial targets debilitating GPA symptoms in ears, nose, and throat
NCT ID NCT07176546
Summary
This study is testing whether adding the medication TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease. About 30 participants with active GPA affecting these areas will receive either TAVNEOS or a placebo pill along with their regular treatment for one year. Researchers will measure whether the drug helps reduce inflammation and symptoms while allowing patients to use less steroid medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack Meridian School of Medicine - Advanced Lung and Airway Center
Edison, New Jersey, 08820, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital for Special Surgery
New York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.